Next-Generation Hemostatic System

Publication ID: 24-11857564_0010_PTD
Published: October 28, 2025
Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Next-Generation Hemostatic System,” Published Technical Disclosure No. 24-11857564_0010_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857564_0010_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,564.

Summary of the Inventive Concept

A futuristic hemostatic system that leverages cutting-edge technologies to revolutionize bleeding control, offering unparalleled efficacy, convenience, and safety.

Background and Problem Solved

The original patent's hemostatic composition, comprising an anion exchanger and a calcium salt, has limitations in terms of application, delivery, and biocompatibility. The new inventive concept addresses these limitations by integrating advanced technologies to create a more efficient, user-friendly, and adaptable system for inducing hemostasis.

Detailed Description of the Inventive Concept

The next-generation hemostatic system consists of a portable device housing a hemostatic composition, a sensor for detecting bleeding, and a nanocarrier-based delivery system. The system can be worn as a wearable device, featuring a micro-needling system for delivering the composition to the site of bleeding. Alternatively, the composition can be applied through an electrostatically-charged spray nozzle. The hemostatic composition itself comprises an anion exchanger, a calcium salt, and a bio-absorbable polymer matrix, designed to dissolve over time, eliminating the need for removal.

Novelty and Inventive Step

The new claims introduce a paradigm shift in hemostatic technology by integrating advanced delivery systems, sensors, and wearable devices, which are not obvious extensions of the original patent's composition-based approach.

Alternative Embodiments and Variations

Other embodiments of the inventive concept could include implantable devices, injectable compositions, or even bio-printed matrices. Variations may involve different types of sensors, delivery mechanisms, or bio-absorbable materials.

Potential Commercial Applications and Market

The next-generation hemostatic system has vast commercial potential in the medical, military, and emergency response industries, offering a game-changing solution for bleeding control and wound management.

Field of Art

Biomedical engineering, specifically hemostatic compositions and medical device technologies focused on wound treatment and bleeding control

Person of Ordinary Skill (PHOSITA) Profile

A biomedical engineer or medical device researcher with expertise in materials science, polymer chemistry, and advanced drug delivery systems, holding at least a master's degree with 3-5 years of specialized experience in hemostatic technologies

Obviousness Rationale

A PHOSITA would recognize that the published technical disclosure represents predictable variations of the source patent's core hemostatic composition technology. The fundamental chemical principles of anion exchangers and calcium salts remain consistent, while the delivery mechanisms represent logical extensions of known medical device design principles. The proposed variations demonstrate incremental improvements that would be obvious to a skilled practitioner seeking to optimize hemostatic interventions.

Obvious Combinations & Variations

Source Patent Element
Hemostatic composition with anion exchanger and calcium salt
PTD Variation
Integrating the composition into a wearable device with micro-needling delivery system
Obviousness Reasoning
Combining known hemostatic materials with advanced drug delivery technologies is a predictable design choice in medical device engineering, representing a standard approach to improving treatment accessibility and patient convenience
Source Patent Element
Composition devoid of blood clotting proteins
PTD Variation
Adding sensor-triggered application mechanism
Obviousness Reasoning
Incorporating electronic sensing technologies into medical compositions is a well-established technique for creating smart, responsive medical interventions, representing an obvious technological progression
Source Patent Element
Matrix-bound anion exchanger
PTD Variation
Bio-absorbable polymer matrix designed for controlled dissolution
Obviousness Reasoning
Modifying material degradation characteristics is a standard approach in biomaterials engineering, with predictable outcomes for improving patient treatment and reducing post-intervention complications
Source Patent Element
Liquid or slurry hemostatic composition
PTD Variation
Electrostatically-charged spray nozzle delivery mechanism
Obviousness Reasoning
Exploring alternative application methods using established electrostatic principles represents an obvious technological extension for improving composition distribution and medical intervention effectiveness
Source Patent Element
Hemostatic composition with specific chemical components
PTD Variation
Nanocarrier-based delivery system for targeted application
Obviousness Reasoning
Implementing nanocarrier technologies for improved drug delivery is a predictable advancement in medical technology, representing a logical progression of existing compositional approaches
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857564, the claimed variations in the published technical disclosure would be considered obvious to a person having ordinary skill in the art. The incremental technological advancements represent predictable combinations of known hemostatic composition principles with established medical device design techniques, thereby rendering potential derivative claims non-patentable under standard obviousness analysis.

Original Patent Information

Patent NumberUS 11,857,564
TitleHemostatic composition comprising an anion exchanger and a calcium salt
Assignee(s)Omrix Biopharmaceuticals Ltd.